Cadila Healthcare Ltd. an innovative, global pharmaceutical company received approval from the USFDA for a seizure treatment drug, vigabatrin tablets in the strength of 500 mg, which is capable of reducing the frequency of seizures in both adults and kids who haven't been able to manage their seizures with existing treatments by preventing the breakdown of GABA, a naturally occurring tranquilizer, in the brain.
Encoded Therapeutics Inc. received over USD 130 million to fund the initial human clinical studies of ETX101, which was given classifications as an orphan drug and a rare pediatric condition by the American Food and Drug Administration (FDA). Furthermore, ETX101 was created to raise NaV1.1-alpha levels to prepare it for the clinic and beyond, and to attract some of the most knowledgeable senior leaders in gene therapy.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5280
Published Date: Sep 28, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing child population and the growing research & development are the major factors driving the growth of the market.
The market size of Dravet Syndrome Treatment is anticipated to attain a CAGR of 11% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc.
The SGDs segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.